Nancy Zeleznik-Le, PhD | Loyola Medicine

Nancy Zeleznik-Le, PhD

Cancer Biology

Chair, Department of Cancer Biology

Languages Spoken


Clinical Expertise



Medical Education

Medical School

Board Certification


  • NKG2D signaling certifies effector CD8 T cells for memory formation. Perez C, Prajapati K, Burke B, Plaza-Rojas L, Zeleznik-Le NJ, Guevara-Patino JA., Journal for immunotherapy of cancer
  • Publisher Correction: miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Li, Z; Huang, H; Chen, P; He, M; Li, Y; Arnovitz, S; Jiang, X; He, C; Hyjek, E; Zhang, J; Zhang, Z; Elkahloun, A; Cao, D; Shen, C; Wunderlich, M; Wang, Y; Neilly, MB; Jin, J; Wei, M; Lu, J; Valk, PJM; Delwel, R; Lowenberg, B; Le Beau, MM; Vardiman, J; Mulloy, JC; Zeleznik-Le, NJ; Liu, PP; Zhang, J; Chen, J, Nature communications
  • Adolescent binge-pattern alcohol exposure alters genome-wide DNA methylation patterns in the hypothalamus of alcohol-naive male offspring Asimes, A.; Torcaso, A.; Pinceti, E.; Kim, C. K.; Zeleznik-Le, N. J.; Pak, T. R., Alcohol (Fayetteville, N.Y.)
View All ResearchShow Less
  • Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients Achille, N. J.; Othus, M.; Phelan, K.; Zhang, S.; Cooper, K.; Godwin, J. E.; Appelbaum, F. R.; Radich, J. P.; Erba, H. P.; Nand, S.; Zeleznik-Le, N. J., Leukemia research
  • One Step Forward in the Challenging Arena of MLL-AF4 Leukemia Zeleznik-Le, N. J., CANCER CELL
  • The miR-17 approximately 92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1 Mian, Y. A.; Zeleznik-Le, N. J., Leukemia research
  • Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di- and Tri-methylation on Target Genes and Transformation Potential Kuntimaddi, A.; Achille, N. J.; Thorpe, J.; Lokken, A. A.; Singh, R.; Hemenway, C. S.; Adli, M.; Zeleznik-Le, N. J.; Bushweller, J. H., Cell reports
  • FAK is required for c-Met/beta-catenin-driven hepatocarcinogenesis Shang, N.; Arteaga, M.; Zaidi, A.; Stauffer, J.; Cotler, S. J.; Zeleznik-Le, N. J.; Zhang, J.; Qiu, W., Hepatology (Baltimore, Md.)
  • FAK Mediates a Compensatory Survival Signal Parallel to PI3K-AKT in PTEN-Null T-ALL Cells You, D.; Xin, J.; Volk, A.; Wei, W.; Schmidt, R.; Scurti, G.; Nand, S.; Breuer, E. K.; Kuo, P. C.; Breslin, P.; Kini, A. R.; Nishimura, M. I.; Zeleznik-Le, N. J.; Zhang, J., Cell reports
  • Introduction to progress and promise of epigenetics for diagnosis and therapy in cancer Zeleznik-Le, N. J., Cancer genetics
  • WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia Brockway, S.; Zeleznik-Le, N. J., Cancer genetics
  • Importance of a specific amino acid pairing for murine MLL leukemias driven by MLLT1/3 or AFF1/4 Lokken, A. A.; Achille, N. J.; Chang, M. J.; Lin, J. J.; Kuntimaddi, A.; Leach, B. I.; Malik, B.; Nesbit, J. B.; Zhang, S.; Bushweller, J. H.; Zeleznik-Le, N. J.; Hemenway, C. S., Leukemia research
  • In memoriam: Janet D. Rowley MD (April 5, 1925-December 17, 2013)., Zeleznik-Le, NJ; Testa, JR, Cancer genetics
  • Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. Velu, CS; Chaubey, A; Phelan, JD; Horman, SR; Wunderlich, M; Guzman, ML; Jegga, AG; Zeleznik-Le, NJ; Chen, J; Mulloy, JC; Cancelas, JA; Jordan, CT; Aronow, BJ; Marcucci, G; Bhat, B; Gebelein, B; Grimes, HL, The Journal of clinical investigation
  • Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. Risner, LE; Kuntimaddi, A; Lokken, AA; Achille, NJ; Birch, NW; Schoenfelt, K; Bushweller, JH; Zeleznik-Le, NJ, The Journal of biological chemistry
  • p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia Zhang, J.; Seet, C. S.; Sun, C.; Li, J.; You, D.; Volk, A.; Breslin, P.; Li, X.; Wei, W.; Qian, Z.; Zeleznik-Le, N. J.; Zhang, Z.; Zhang, J., Molecular oncology
  • Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML Lokken, A. A.; Zeleznik-Le, N. J., CANCER CELL
  • miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia Li, Z.; Huang, H.; Chen, P.; He, M.; Li, Y.; Arnovitz, S.; Jiang, X.; He, C.; Hyjek, E.; Zhang, J.; Zhang, Z.; Elkahloun, A.; Cao, D.; Shen, C.; Wunderlich, M.; Wang, Y.; Neilly, M. B.; Jin, J.; Wei, M.; Lu, J.; Valk, P. J.; Delwel, R.; Lowenberg, B.; Le Beau, M. M.; Vardiman, J.; Mulloy, J. C.; Zeleznik-Le, N. J.; Liu, P. P.; Zhang, J.; Chen, J., Nature communications
  • Overexpression of Foxn1 attenuates age-associated thymic involution and prevents the expansion of peripheral CD4 memory T cells. Zook, E. C.; Krishack, P. A.; Zhang, S.; Zeleznik-Le, N. J.; Firulli, A. B.; Witte, P. L.; Le, P. T., Blood
  • Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia Mi, S.; Li, Z.; Chen, P.; He, C.; Cao, D.; Elkahloun, A.; Lu, J.; Pelloso, L. A.; Wunderlich, M.; Huang, H.; Luo, R. T.; Sun, M.; He, M.; Neilly, M. B.; Zeleznik-Le, N. J.; Thirman, M. J.; Mulloy, J. C.; Liu, P. P.; Rowley, J. D.; Chen, J., Proceedings of the National Academy of Sciences of the United States of America
  • Glycogen synthase kinase-3 and leukemia: restoring the balance Birch, N. W.; Zeleznik-Le, N. J., CANCER CELL
  • Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes Chang, M. J.; Wu, H.; Achille, N. J.; Reisenauer, M. R.; Chou, C. W.; Zeleznik-Le, N. J.; Hemenway, C. S.; Zhang, W., Cancer research
  • MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets Mian, Y. A.; Zeleznik-Le, N. J., Current Drug Targets
  • Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia Cierpicki, T.; Risner, L. E.; Grembecka, J.; Lukasik, S. M.; Popovic, R.; Omonkowska, M.; Shultis, D. D.; Zeleznik-Le, N. J.; Bushweller, J. H., Nature structural & molecular biology
  • Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Popovic, R.; Riesbeck, L. E.; Velu, C. S.; Chaubey, A.; Zhang, J.; Achille, N. J.; Erfurth, F. E.; Eaton, K.; Lu, J.; Grimes, H. L.; Chen, J.; Rowley, J. D.; Zeleznik-Le, N. J., Blood
  • Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Chen, J.; Santillan, D. A.; Koonce, M.; Wei, W.; Luo, R.; Thirman, M. J.; Zeleznik-Le, N. J.; Diaz, M. O., Cancer research
  • MLL protects CpG clusters from methylation within the Hoxa9 gene maintaining transcript expression., Erfurth, F. E.; Popovic, R.; Grembecka, J.; Cierpicki, T.; Theisler, C.; Xia, Z. B.; Stuart, T.; Diaz, M. O.; Bushweller, J. H.; Zeleznik-Le, N. J., Proceedings of the National Academy of Sciences of the United States of America
  • Transcriptional complexity of the HOXA9 locus Popovic, R.; Erfurth, F.; Zeleznik-Le, N., Blood cells, molecules & diseases
  • Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas Baron, B. W.; Zeleznik-Le, N.; Baron, M. J.; Theisler, C.; Huo, D.; Krasowski, M. D.; Thirman, M. J.; Baron, R. M.; Baron, J. M., Proceedings of the National Academy of Sciences of the United States of America
  • Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype. Santillan, D. A.; Theisler, C. M.; Ryan, A. S.; Popovic, R.; Stuart, T.; Zhou, M. M.; Alkan, S.; Zeleznik-Le, N. J., Cancer research
  • MLL: how complex does it get? Popovic, R.; Zeleznik-Le, N. J., Journal of cellular biochemistry
  • The MLL fusion gene MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression., Xia, Z. B.; Popovic, R.; Chen, J.; Theisler, C.; Stuart, T.; Santillan, D. A.; Erfurth, F.; Diaz, M. O.; Zeleznik-Le, N. J., Proceedings of the National Academy of Sciences of the United States of America
  • Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16) Zhang, Y.; Zeleznik-Le, N.; Emmanuel, N.; Jayathilaka, N.; Chen, J.; Strissel, P.; Strick, R.; Li, L.; Neilly, M. B.; Taki, T.; Hayashi, Y.; Kaneko, Y.; Schlegelberger, B.; Rowley, J. D., Genes, chromosomes & cancer
  • Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin in a patient with AML-M2, Vazquez, I.; Lahortiga, I.; Agirre, X.; Larrayoz, M. J.; Vizmanos, J. L.; Ardanaz, M. T.; Zeleznik-Le, N. J.; Calasanz, M. J.; Odero, M. D., Leukemia
  • Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation Mujtaba, S.; He, Y.; Zeng, L.; Yan, S.; Plotnikova, O.; Sachchidanand; Sanchez, R.; Zeleznik-Le, N. J.; Ronai, Z.; Zhou, M. M., Molecular cell
  • A t(11;15) fuses MLL to two different genes AF15q14 and a novel gene MPFYVE on chromosome 15, Chinwalla, V.; Chien, A.; Odero, M.; Neilly, M. B.; Zeleznik-Le, N. J.; Rowley, J. D., Oncogene
  • Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14) Kuefer, M. U.; Chinwalla, V.; Zeleznik-Le, N. J.; Behm, F. G.; Naeve, C. W.; Rakestraw, K. M.; Mukatira, S. T.; Raimondi, S. C.; Morris, S. W., Oncogene
  • MLL repression domain interacts with histone deacetylases the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein., Xia, Z. B.; Anderson, M.; Diaz, M. O.; Zeleznik-Le, N. J., Proceedings of the National Academy of Sciences of the United States of America
  • Polymorphisms in the MLL breakpoint cluster region (BCR) Echlin-Bell, D. R.; Smith, L. L.; Li, L.; Strissel, P. L.; Strick, R.; Gupta, V.; Banerjee, J.; Larson, R.; Relling, M. V.; Raimondi, S. C.; Hayashi, Y.; Taki, T.; Zeleznik-Le, N.; Rowley, J. D., Human genetics
  • A novel gene MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome, Odero, M. D.; Vizmanos, J. L.; Roman, J. P.; Lahortiga, I.; Panizo, C.; Calasanz, M. J.; Zeleznik-Le, N. J.; Rowley, J. D.; Novo, F. J., Genes, chromosomes & cancer
  • Mammalian septins nomenclature Macara, I. G.; Baldarelli, R.; Field, C. M.; Glotzer, M.; Hayashi, Y.; Hsu, S. C.; Kennedy, M. B.; Kinoshita, M.; Longtine, M.; Low, C.; Maltais, L. J.; McKenzie, L.; Mitchison, T. J.; Nishikawa, T.; Noda, M.; Petty, E. M.; Peifer, M.; Pringle, J. R.; Robinson, P. J.; Roth, D.; Russell, S. E.; Stuhlmann, H.; Tanaka, M.; Tanaka, T.; Trimble, W. S.; Ware, J.; Zeleznik-Le, N. J.; Zieger, B., Molecular biology of the cell
  • The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis Baron, B. W.; Anastasi, J.; Thirman, M. J.; Furukawa, Y.; Fears, S.; Kim, D. C.; Simone, F.; Birkenbach, M.; Montag, A.; Sadhu, A.; Zeleznik-Le, N.; McKeithan, T. W., Proceedings of the National Academy of Sciences of the United States of America
  • Retroviral transduction model of mixed lineage leukemia fused to CREB binding protein Liedman, D.; Zeleznik-Le, N., Current opinion in hematology
  • The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia Whitman, S. P.; Strout, M. P.; Marcucci, G.; Freud, A. G.; Culley, L. L.; Zeleznik-Le, N. J.; Mrozek, K.; Theil, K. S.; Kees, U. R.; Bloomfield, C. D.; Caligiuri, M. A., Cancer research
  • Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia Lavau, C.; Du, C.; Thirman, M.; Zeleznik-Le, N., The EMBO journal
  • Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation Odero, M. D.; Zeleznik-Le, N. J.; Chinwalla, V.; Rowley, J. D., Genes, chromosomes & cancer
  • DNA structural properties of AF9 are similar to MLL and could act as recombination hot spots resulting in MLL/AF9 translocations and leukemogenesis Strissel, P. L.; Strick, R.; Tomek, R. J.; Roe, B. A.; Rowley, J. D.; Zeleznik-Le, N. J., Human molecular genetics